×
Please click
here
if you are not redirected within a few seconds.
All
News
Videos
Images
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Has Cassava Sciences (SAVA) Outpaced Other Medical Stocks This Year?
Yahoo Movies Canada
Investors focused on the Medical space have likely heard of Cassava Sciences (SAVA), but is the stock performing well in comparison to the...
4 hours ago
Investigation of Cassava Sciences, Inc. (SAVA) Announced by Holzer & Holzer, LLC
ConchoValleyHomepage.com
ATLANTA, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Holzer & Holzer, LLC is investigating whether Cassava Sciences, Inc. (“Cassava” or “the Company”) (NASDAQ: SAVA)...
2 days ago
Is There Any Hope for Cassava Sciences Stock?
The Motley Fool
Key Points. Cassava Sciences stock is down due to questions about some of its research. A lot is riding on its late-stage clinical trials to...
3 months ago
Cassava Sciences' Alzheimer's clinical trials should be halted
STAT
It's time for the FDA to halt Cassava Sciences' Alzheimer's clinical trials ... The Food and Drug Administration should halt Cassava Sciences'...
6 months ago
Cassava Sciences call volume above normal and directionally bullish - TipRanks.com
Tipranks
Bullish option flow detected in Cassava Sciences with 2987 calls trading, 1.1x expected, and implied vol increasing almost 12 points to...
3 days ago
Cassava Sciences (SAVA) Jumps: Stock Rises 9.2%
Yahoo News New Zealand
Cassava Sciences (SAVA) saw a big move last session, as its shares jumped more than 9% on the day, amid huge volumes.
1 day ago
Cassava Sciences: New Year, Same Game Of Smoke And Mirrors (NASDAQ:SAVA)
Seeking Alpha
Cassava Sciences reported 2023 cash of $121.1m, $(97.2m) of net loss and R&D expenses increased to $89.4m. Read more on SAVA stock here.
1 month ago
Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ
GlobeNewswire
AUSTIN, Texas, May 01, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (NASDAQ: SAVA) (“Cassava Sciences” or the "Company") has been advised...
4 days ago
Topline results of Phase 3 studies of simufilam for Alzheimer's...
Alzheimer's News Today
A total of 1929 Alzheimer's patients have enrolled in two simufilam studies, which the FDA said could support its application for approval.
2 months ago
Scientists Investigating Alzheimer's Drug Faulted in Leaked Report
The New York Times
A professor at the City College of New York engaged in “significant research misconduct,” an expert committee concluded.
6 months ago